title: Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer?
abstract: OBJECTIVE
  To investigate the relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer.
  
  
  METHODS
  Data of 73 patients were retrospectively analyzed. Relations between SUVmax value, clinical stage, tumor grade and breast cancer molecular subtypes were analyzed by using one-way ANOVA and x(2) tests. Correlations between age, ki-67 scores and SUVmax were evaluated by using Pearson's correlation test. A p value <0.05 was considered statistically significant.
  
  
  RESULTS
  Median SUVmax values for clinical stages 1, 2 and 3 were 5 (range 2.1-4.1), 10.6 (range 2.9-19.6), and 12.2 (range 3.2-23.3), respectively. Statistically significant difference was noticed between stage 1 and 2 (p=0.014) and stage 1 and 3 (p=0.001). Median SUVmax values of triple negative, luminal A, luminal B and non-luminal HER2 positive groups were 14.4 (range 6.6-23.3), 8.2 (range 2.1-18.2), 10.1 (range 3.5-19.6), and 14 (range 4.1-22.9), respectively. Statistically significant differences were noticed in SUVmax values between triple-negative and luminal A groups (p=0.005) and between non-luminal HER2 positive and luminal A groups (p=0.02). Median SUVmax values of grade 1, 2 and 3 were 5.7 (range 2.1-18.2), 9.5 (range 2.2-21.3), and 11.6 (range 3.5-23), respectively. Statistically significant difference was noticed only between SUVmax values of grade 1 and 3 (p=0.035). There was negative correlation between age and SUVmax value (r=-0.23, p=0.047) and positive correlation between ki-67 and SUVmax value (r=0.43, p=0.016).
  
  
  CONCLUSIONS
  There were significant positive relations between PET-CT SUVmax value and clinical stage, tumor grade, and certain breast cancer molecular subtypes (triple-negative and non-luminal HER2 positive groups. Moreover, positive correlation was found between SUVmax value and ki-67 and negative correlation between SUVmax value and age.
authors.affiliation: Department of Medical Oncology, Akdeniz University, Medical School, Antalya, Bakirkoy Education and Research Hospital, Istanbul, Turkey.
authors.forename: Deniz
authors.initials: D
authors.lastname: Tural
authors.forename: Derya
authors.initials: D
authors.lastname: Kivrak Salim
authors.forename: Hasan
authors.initials: H
authors.lastname: Mutlu
authors.forename: Metin
authors.initials: M
authors.lastname: Erkilic
authors.forename: Seyda
authors.initials: S
authors.lastname: Gunduz
authors.forename: Melek
authors.initials: M
authors.lastname: Karakurt
authors.forename: Fatma
authors.initials: F
authors.lastname: Musri
authors.forename: Savas
authors.initials: S
authors.lastname: Tuna
authors.forename: Adil
authors.initials: A
authors.lastname: Boz
authors.forename: Funda
authors.initials: F
authors.lastname: Aydin
authors.forename: Binnur
authors.initials: B
authors.lastname: Karayalcin
authors.forename: Hakan
authors.initials: H
authors.lastname: Bozcuk
authors.forename: Hasan
authors.initials: H
authors.lastname: Senol Coskun
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D006801:Humans; D019394:Ki-67 Antigen / Q000032:analysis / Q000737:chemistry; D008875:Middle Aged; D049268:Positron-Emission Tomography; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D019394:Ki-67 Antigen; D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human